BioSpace News Archive

Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced that a new subsidiary created to work with the company’s Artificial Intelligence (AI) Deep Learning Platform has generated initial revenue of approximately $4.2 million from Non-Fungible Token (NFT) sales.

Altamira Therapeutics Ltd., a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced that the first group of patients has been randomized in a clinical trial with Bentrio™ in house dust mite allergic rhinitis.

AscellaHealth, a global specialty pharmacy and healthcare solutions company, today announces its strategic alliance with Optime Care to further enhance its ability to become a leader in Specialty Pharmacy (SP) services and establish a strong trajectory for growth.

Kura Oncology, Inc. (Nasdaq: KURA), today announced dose administration for the first patient in KURRENT, the Company’s Phase 1/2 clinical trial of tipifarnib in combination with alpelisib in patients with HRAS- and/or PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC).

City of Hope doctors presented data on an investigational bispecific antibody for multiple myeloma and the CMVPepVax, a City of Hope-developed vaccine against the cytomegalovirus, at this year’s ASH Annual Meeting.

Vero Diagnostics, a CLIA high complexity & CAP certified, state-of-the-art laboratory, announced the launch of the Baebies® FINDER® 1.5 ultra-rapid SARS-CoV-2 RT-PCR testing platform to Vero Diagnostics customers in Los Angeles.

AstraZeneca’s EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralizing activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new preclinical data.

Curebase, a company committed to democratizing access to clinical studies, is pleased to have served as the technology partner for metaMe Health’s Regulora®, the first FDA-authorized treatment of any kind specifically for abdominal pain associated with irritable bowel syndrome (IBS) in adults.

Implicity, a leader in remote patient monitoring and cardiac data management solutions, today announced FDA clearance for a novel medical algorithm that analyzes ECG data from Implantable Loop Recorders (ILRs).

Surgical Innovation Associates, Inc., a growth-stage medical device company that manufacturers fully-resorbable, biosynthetic implants for the high-growth, multi-billion-dollar markets of plastic, reconstructive, and general surgery, announced the successful close of its Series B round of financing.